Xenon Pharmaceuticals Stock News

Equities analysts forecast that Xenon Pharmaceuticals Inc. (NASDAQ:XENE) will post $7.10 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Xenon Pharmaceuticals earnings, with estimates ranging from $4.00 million to $8.80 million. Xenon Pharmaceuticals posted sales of $5.15 million in the same quarter last year, which would []

Analysts expect that Xenon Pharmaceuticals Inc. (NASDAQ:XENE) will report earnings of ($0.42) per share for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Xenon Pharmaceuticals earnings, with the lowest EPS estimate coming in at ($0.67) and the highest estimate coming in at ($0.29). Xenon Pharmaceuticals posted earnings per share of []

Xenon Pharmaceuticals Inc. (NASDAQ:XENE)s stock price dropped 6% during mid-day trading on Monday . The company traded as low as $27.11 and last traded at $27.26. Approximately 3,412 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 736,805 shares. The stock had previously closed at $28.99. XENE has []

Equities research analysts expect Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to announce sales of $7.10 million for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Xenon Pharmaceuticals earnings. The lowest sales estimate is $4.00 million and the highest is $8.80 million. Xenon Pharmaceuticals posted sales of $5.15 million during the same quarter []

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Research analysts at SVB Leerink dropped their FY2021 earnings estimates for shares of Xenon Pharmaceuticals in a research report issued on Wednesday, November 10th. SVB Leerink analyst M. Goodman now anticipates that the biopharmaceutical company will earn ($1.60) per share for the year, down from their previous estimate of ($1.50). []

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Simon N. Pimstone sold 17,557 shares of Xenon Pharmaceuticals stock in a transaction on Monday, November 15th. The stock was sold at an average price of $31.33, for a total value of $550,060.81. The transaction was disclosed in a document filed with the SEC, which is available through this link. []

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Investment analysts at Wedbush upped their FY2021 earnings per share estimates for shares of Xenon Pharmaceuticals in a research note issued on Thursday, November 11th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings per share of ($1.79) for the year, up from their previous estimate […]

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Investment analysts at William Blair upped their FY2021 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a note issued to investors on Wednesday, November 10th. William Blair analyst T. Lugo now expects that the biopharmaceutical company will earn ($1.54) per share for the year, up from their []

BURNABY, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon's Preside

Xenon Pharmaceuticals' (XENE) CEO Ian Mortimer on Q3 2021 Results - Earnings Call Transcript

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 18.18% and 4.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stoc

XENE stock is a valuable stock market lesson about separating great expectations for stocks from the company's true fundamentals. The post Xenon Pharmaceuticals Has a Great Story But Too High a Price

Xenon just delivered strong clinical trial results and leveraged that into a strong fundraising effort. That has XENE stock in a good place going forward.

XENE stock deserved to move higher but was stuck for months -- until a game-changing epilepsy treatment put Xenon in the spotlight again. The post New Clinical Results Make Xenon Pharmaceuticals' Stoc

BURNABY, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announc